IBRX Live signals | Maximize Profits with Getagraph.com

BUY 103746 min ago

@ $4.52

Issued: 14 Feb 2024 @ 13:58

Return: 62.79%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 4.24 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	39.08M
Average Volume	4.85M
Market Cap	4.95B
EPS	$-0.350 ( 2024-03-20 )
Next earnings date	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.117 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Simon Barry J.	Buy	159 146	Stock Option (right to buy)
2024-02-22	Simon Barry J.	Buy	45 731	Restricted Stock Units
2024-02-22	Lauer Regan J	Buy	42 439	Stock Option (right to buy)
2024-02-22	Lauer Regan J	Buy	12 195	Restricted Stock Units
2024-02-22	Sachs David C.	Buy	424 390	Stock Option (right to buy)

INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 \| Sell: 921 083

Volume Correlation

Long: 0.53 (weak)

Short: -0.15 (neutral)

Signal:(48.073) Neutral

ImmunityBio, Inc. Correlation

10 Most Positive Correlations
SIRI	0.928
RGF	0.928
FGBI	0.925
AROW	0.921
ALRS	0.92
GNTY	0.92
CBNK	0.915
GSMG	0.914
GOOD	0.906
ALLK	0.906

10 Most Negative Correlations
RIVE	-0.933
DSEY	-0.93
DUOL	-0.927
AMPH	-0.926
RAM	-0.919
INTA	-0.919
PLYA	-0.918
ALTR	-0.91
DAIO	-0.909
MLTX	-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ImmunityBio, Inc. Correlation - Currency/Commodity

-0.74
( moderate negative )

-0.69
( moderate negative )

0.00
( neutral )

-0.65
( weak negative )

0.00
( neutral )

-0.08
( neutral )

ImmunityBio, Inc. Financials

Annual	2023
Revenue:	$622 000
Gross Profit:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2023
Revenue:	$622 000
Gross Profit:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2022
Revenue:	$240 000
Gross Profit:	$-23.95M (-9 980.00 %)
EPS:	$-1.040

FY	2021
Revenue:	$934 000
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.